SCHEMBL7031940

SCHEMBL7031940

CCC(I)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL634334 0.97 SHBG (0.56)
SCHEMBL12094462 0.94
SCHEMBL19539461 0.88
SCHEMBL9971146 0.74 SHBG (0.43)
SCHEMBL19799387 0.72
SCHEMBL16864424 0.72 EPHX1 (0.35)
SCHEMBL16026654 0.72 SHBG (0.41)
SCHEMBL28027504 0.72 SHBG (0.30)
SCHEMBL18951345 0.71 SHBG (0.36)
SCHEMBL2342491 0.71 SHBG (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348023-B9 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORP (US) 2017-03-08 EP disclosed
US-20030055297-A1 An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation ABBOTT LABORATORIES 2003-03-20 US disclosed
WO-2002081441-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS ABBOTT LABORATORIES (US) 2002-10-17 WO disclosed
EP-0858340-A4 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO INC (US) 1999-12-29 EP disclosed
EP-0858340-A1 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1998-08-19 EP disclosed
WO-1997016189-A1 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1997-05-09 WO disclosed